Ada Patient Finder -- Daily Briefing

Friday, February 13, 2026 -- 7:00 AM ET
Snapshot: 2026-02-13
Pipeline Snapshot
€93,339,726
Total Pipeline (Unweighted)
€7,581,527
Weighted Pipeline
126
Open Opps
€0
Closing This Quarter
1
Calls Yesterday
3.1
7-Day Avg Calls
61
Stale Deals
Stage Moves (Last 24h)
Merck Patient Finder PAH(Oncology) Winrevair US Advanced
Moved from Qualification | 5% to Discovery | 10% (Karen VanOverberghe)
€421,260
Bayer US Nubeqa Advanced
Moved from Discovery | 10% to Qualification | 5% (Karen VanOverberghe)
€421,260
Biogen US Advanced
Moved from Discovery | 10% to Qualification | 5% (Ashley Cudini)
€421,260
Relevate health Advanced
Moved from Qualification | 5% to Discovery | 10% (Jacob Plummer)
€84,252
VERTEX | AMKD | US Advanced
Moved from Discovery | 10% to Qualification | 5% (Ashley Cudini)
€421,260
Jazz Pharmaceuticals US- Xywav Advanced
Moved from Discovery | 10% to Qualification | 5% (Ashley Cudini)
€421,260
Bayer US - Lynkuet (Elinzanetant) Advanced
Moved from Discovery | 10% to Qualification | 5% (Karen VanOverberghe)
€421,260
argenx US Vyvgart gMG Advanced
Moved from Discovery | 10% to Qualification | 5% (Ashley Cudini)
€421,260
Pipeline Changes
UCB MG-Rare Patient Finder New
Karen VanOverberghe | Qualification | 5% | €421
EMD Serono | MS & Rare Disease | US Removed
Eran Desheh | Qualification | 5%
Novartis Kesimpta Patient Finder Removed
Karen VanOverberghe | Qualification | 5%
Incyte Jakafi Patient Finder Removed
Karen VanOverberghe | Qualification | 5%
BridgeBio Pharma | Attruby | ATTR-CM Removed
Ashley Cudini | Qualification | 5%
Alnylam Pharmaceuticals | Amvuttra | ATTR-CM Removed
Ashley Cudini | Qualification | 5%
Roche LatAm Removed
Ashley Cudini | Qualification | 5%
Ipsen Patient Finder Removed
Karen VanOverberghe | Qualification | 5%
Clinical University Childrens Hospital, Latvia (BUKS) Removed
Adel Baluch | Discovery | 10%
Stale Deals (14+ Days Since Last Contact)
Crohns Colitis Foundation 379d No Contact
Jacob Plummer | Qualification | 5% | €421,260
Ontario Enhancements - Suicide Pop Up - Delivery 268d No Contact
Simon Wolpert | Qualification | 5% | €247,586
Ontario SOW9 - Health Care Connect (Primary Care Attachment) - Planning Only 209d No Contact
Simon Wolpert | Proposal | 30% | €30,948
Astrazeneca - Wainua 162d No Contact
Usaid Cheema | Qualification | 5% | €500,000
Walgreens/Boots 158d No Contact
Randal Whitmore | Qualification | 5% | €421,260
Patient Finder for Temple Health 157d No Contact
Randal Whitmore | Qualification | 5% | €421,260
Health 811 SOW9 - HCC + Survey Planning + Delivery 150d No Contact
Simon Wolpert | Proposal | 30% | €92,844
DKV Seguros 144d No Contact
Johannes Vonhuelsen | Discovery | 10% | €486,000
GSK - Shingrix 128d No Contact
Usaid Cheema | Qualification | 5% | €421,260
Alberta Health Services - Patient Portal (via Orion & Telus/IBM) 97d No Contact
Simon Wolpert | Qualification | 5% | €4,796,991
+51 more stale deals
No Decision Maker Engaged
AbbVie - Botox No DM
Usaid Cheema | Qualification | 5% | €421,260
AbbVie - Rinvoq No DM
Usaid Cheema | Qualification | 5% | €421,260
AbbVie - Vraylar No DM
Usaid Cheema | Qualification | 5% | €500,000
ACADIA Pharmaceuticals | Daybue | Rett syndrome No DM
Usaid Cheema | Qualification | 5% | €421,260
Acorda Therapeutics | Ampyra | Multiple sclerosis (improve walking) No DM
Usaid Cheema | Qualification | 5% | €421,260
Aetna a CVS Health Company No DM
Simon Wolpert | Qualification | 5% | €252,756
Alberta Health Services - Patient Portal (via Orion & Telus/IBM) No DM
Simon Wolpert | Qualification | 5% | €4,796,991
Alkermes - Libalvi No DM
Usaid Cheema | Qualification | 5% | €500,000
+18 more
Flagged Calls (< 3.0)
No flagged calls
Calls Yesterday (1)
Voramedic call 48m
Participants:
Top Deals by Value
GNAL
Qualification | 5%
€20,500,000
Biogen | Friedreichs Ataxia | Global - Phase 2
Qualification | 5%
€6,000,000
Blue Shield of California
Proposal | 30%
€5,476,380
Alberta Health Services - Patient Portal (via Orion & Telus/IBM)
Qualification | 5%
€4,796,991
Resmed Phase 2
Qualification | 5%
€2,527,560
SANOFI | Diabetes | TZIELD | US - Phase 2
Discovery | 10%
€2,527,560
Biogen Germany FA extension
Discovery | 10%
€2,100,000
Blue Cross Blue Shield Arizona
Qualification | 5%
€1,432,284
Pharma Intel -- Urgent
**SANOFI CEO CHANGE: Paul Hudson OUT, Belen Garijo IN (effective Apr 29)**
Sanofi unexpectedly replaced CEO Paul Hudson on Feb 12. Hudson departs Feb 17. Belen Garijo (outgoing Merck KGaA CEO) takes over after AGM on April 29. Interim CEO: Olivier Charmeil (EVP General Medicines). Sanofi shares dropped ~6% on the news. Gari
- Source: [MarketScreener](https://www.marketscreener.com/news/surprising-leadership-change-at-sanofi-outgoing-merck-ceo-to-take-the-helm-ce7e5ad2d181f423), [DCAT](https://www.dcatvci.org/top-industry-news/sanofi-appoints-new-ceo/)
**IMPACT ON PATIENT FINDER:** This is a critical development. Paul Hudson was a warm contact for Daniel. The new CEO Garijo is an unknown quantity for Ada's relationship. Outreach strategy needs immediate reassessment:
1. Daniel should consider reaching out to Hudson before Feb 17 departure -- he may land elsewhere in pharma and remain a contact
2. Olivier Charmeil (interim CEO) may be a bridge contact during transition
3. Garijo previously spent 15 years at Sanofi before Merck KGaA -- she knows the organization deeply
4. Garijo's R&D focus could be favorable for Patient Finder if positioned as innovation
Meetings Today
8:30 AM
Prepare avm calc
10:30 AM
Albrecht
1:00 PM
Prof. Christopher
2:00 PM
Strategy Block
5:15 PM -- claire.novorol@ada.com
Travel
5:45 PM -- claire.novorol@ada.com
Anders' Surprise Birthday Party
9:30 PM -- claire.novorol@ada.com
Travel
System Health
Cron Jobs0 active
Stale Tasks11
Generated by Ada Cockpit | 2026-02-13 07:00 ET